{"protocolSection":{"identificationModule":{"nctId":"NCT01342965","orgStudyIdInfo":{"id":"YO25121"},"organization":{"fullName":"Hoffmann-La Roche","class":"INDUSTRY"},"briefTitle":"A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations","officialTitle":"A Multicenter, Open-label, Randomized Phase III Study to Evaluate the Efficacy and Safety of Erlotinib (Tarceva®) Versus Gemcitabine/Cisplatin as the First-line Treatment for Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) Patients With Mutations in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor (EGFR) in Their Tumors"},"statusModule":{"statusVerifiedDate":"2015-02","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2011-03"},"primaryCompletionDateStruct":{"date":"2012-07","type":"ACTUAL"},"completionDateStruct":{"date":"2014-04","type":"ACTUAL"},"studyFirstSubmitDate":"2011-04-26","studyFirstSubmitQcDate":"2011-04-26","studyFirstPostDateStruct":{"date":"2011-04-27","type":"ESTIMATED"},"resultsFirstSubmitDate":"2015-02-05","resultsFirstSubmitQcDate":"2015-02-05","resultsFirstPostDateStruct":{"date":"2015-02-24","type":"ESTIMATED"},"lastUpdateSubmitDate":"2015-02-05","lastUpdatePostDateStruct":{"date":"2015-02-24","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Hoffmann-La Roche","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"This open-label, randomized, parallel arm study assessed the efficacy and safety of Tarceva (erlotinib) versus gemcitabine/cisplatin combination chemotherapy as first-line treatment in patients with stage IIIB/IV non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations in their tumours. Patients were randomized to receive either Tarceva 150 mg orally daily or 3-week cycles of gemcitabine 1250 mg/m\\^2 intravenously (iv) on Days 1 and 8 plus cisplatin 75 mg/m\\^2 iv on Day 1."},"conditionsModule":{"conditions":["Non-Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":217,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Erlotinib","type":"EXPERIMENTAL","description":"Participants received erlotinib 150 mg orally once daily until progressive disease or unacceptable toxicity.","interventionNames":["Drug: Erlotinib"]},{"label":"Chemotherapy","type":"ACTIVE_COMPARATOR","description":"Participants received gemcitabine 1250 mg/m\\^2 intravenously (IV) on Days 1 and 8 and cisplatin 75 mg/m\\^2 IV on Day 1 of every 3 week cycle until disease progression, unacceptable toxicity, or a total of 4 cycles, whichever came first.","interventionNames":["Drug: Chemotherapy"]}],"interventions":[{"type":"DRUG","name":"Erlotinib","description":"Erlotinib was supplied as tablets.","armGroupLabels":["Erlotinib"],"otherNames":["Tarceva"]},{"type":"DRUG","name":"Chemotherapy","description":"Cisplatin and gemcitabine were locally sourced with commercial products.","armGroupLabels":["Chemotherapy"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Investigator-assessed Duration of Progression-free Survival","description":"The duration of progression-free survival was defined as the time from randomization to disease progression (PD) or death from any cause, whichever occurs first. PD was defined as: (1) At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this may include the baseline sum). The sum must also demonstrate an absolute increase of at least 5 mm. (2) An unequivocal progression of existing non-target lesions. When the patient has measurable disease, the overall tumor burden must have increased sufficiently to merit discontinuation of therapy. When the patient has only non-measurable disease, the increase in overall disease burden should be comparable in magnitude to the increase that would be required to declare PD for measurable disease. (3) The appearance of new malignant lesions.","timeFrame":"Baseline to the data cut-off date of 20 Jul 2012 (1 year, 4 months)"}],"secondaryOutcomes":[{"measure":"Percentage of Responders as Assessed by the Investigator","description":"A responder was defined as a participant with either a complete response (CR) or a partial response (PR), as determined using the Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. A CR was defined as: (1) The disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \\< 10 mm. (2) The disappearance of all non-target lesions and normalization of tumor marker levels. All lymph nodes must be non-pathological in size (\\< 10 mm in the short axis). A PR was defined as: (1) At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. (2) The persistence of 1 or more non-target lesion(s) and/or maintenance of tumor marker levels above normal limits.","timeFrame":"Baseline to the data cut-off date of 19 Nov 2012 (1 year, 8 months)"},{"measure":"Percentage of Participants With Disease Control","description":"A participant with disease control was defined as a participant with either a complete response (CR), a partial response (PR), or stable disease (SD), as determined using RECIST v1.1. A CR was defined as the disappearance of all target lesions (TL). A PR was defined as at least a 30% decrease in the sum of the longest diameter of TLs taking as reference the Baseline sum longest diameter (SLD). SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest SLD since treatment started. For non-TLs, SD was defined as the persistence of 1 or more lesions. PD was defined as at least a 20% increase in the SLD of TLs, taking as reference the smallest SLD recorded since treatment started or the unequivocal progression of existing non-TLs. A SLD for all TLs will be calculated and reported as the Baseline SLD.","timeFrame":"Baseline to the data cut-off date of 19 Nov 2012 (1 year, 8 months)"},{"measure":"Duration of Response","description":"Duration of response was defined as the time from the first documented complete response (CR) or partial response (PR) to the first documented disease progression (PD) or death, whichever occurs first. A CR was defined as the disappearance of all target lesions (TL). A PR was defined as at least a 30% decrease in the sum of the longest diameter (SLD) of TLs taking as reference the Baseline SLD. PD was defined as at least a 20% increase in the SLD of TLs, taking as reference the smallest SLD recorded since treatment started or the unequivocal progression of existing non-TLs.","timeFrame":"Baseline to the data cut-off date of 19 Nov 2012 (1 year, 8 months)"},{"measure":"Overall Survival","description":"Overall survival was defined as the time from the date of randomization to the date of death from any cause.","timeFrame":"Baseline to the end of the study (3 years, 1 month)"},{"measure":"Safety: Incidence of Adverse Events","timeFrame":"36 months"},{"measure":"Quality of Life: Functional Assessment of Chronic Illness Therapy - Lung (FACIT-L) Questionnaire","timeFrame":"approximately 21 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adult participants, ≥ 18 years of age.\n* Locally advanced or recurrent (stage IIIB) or metastatic (stage IV) non-small cell lung cancer.\n* Presence of epidermal growth factor receptor (EGFR) mutations in tumours.\n* Measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 criteria.\n* European Cooperative Oncology Group (ECOG) performance status ≤ 2.\n\nExclusion Criteria:\n\n* Prior exposure to agents directed at the human epidermal receptor (HER) axis (eg, but not limited to erlotinib, gefitinib, cetuximab, or trastuzumab).\n* Prior chemotherapy or systemic anti-neoplastic therapy for advanced disease.\n* Lack of physical integrity of the upper gastrointestinal tract, or malabsorption syndrome, or inability to take oral medication, or active gastroduodenal ulcer disease.\n* Any inflammatory changes of the surface of the eye.\n* ≥ Grade 2 peripheral neuropathy.\n* History of any other malignancies within 5 years, except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer.\n* Brain metastasis or spinal cord compression that has not yet been definitely treated with surgery and/or radiation, or treated but without evidence of stable disease for at least 2 months.\n* Human immunodeficiency virus (HIV) infection.\n* Pregnant, nursing, or lactating women.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Clinical Trials","affiliation":"Hoffmann-La Roche","role":"STUDY_DIRECTOR"}],"locations":[{"city":"Beijing","zip":"100071","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"city":"Beijing","zip":"101149","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"city":"Changchun","zip":"130012","country":"China","geoPoint":{"lat":43.88,"lon":125.32278}},{"city":"Chongqing","zip":"400038","country":"China","geoPoint":{"lat":29.56026,"lon":106.55771}},{"city":"Chongqing","zip":"400042","country":"China","geoPoint":{"lat":29.56026,"lon":106.55771}},{"city":"Fuzhou","zip":"350014","country":"China","geoPoint":{"lat":26.06139,"lon":119.30611}},{"city":"Guangzhou","zip":"510080","country":"China","geoPoint":{"lat":23.11667,"lon":113.25}},{"city":"Hangzhou","zip":"310016","country":"China","geoPoint":{"lat":30.29365,"lon":120.16142}},{"city":"Nanjing","zip":"210002","country":"China","geoPoint":{"lat":32.06167,"lon":118.77778}},{"city":"Shanghai","zip":"200030","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"city":"Shanghai","zip":"200032","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"city":"Shanghai","zip":"200433","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"city":"Shantou","zip":"515041","country":"China","geoPoint":{"lat":23.35489,"lon":116.67876}},{"city":"Wuhan","zip":"430023","country":"China","geoPoint":{"lat":30.58333,"lon":114.26667}},{"city":"Xi'an","zip":"710061","country":"China","geoPoint":{"lat":34.25833,"lon":108.92861}},{"city":"Kampung Baharu Nilai","zip":"71800","country":"Malaysia","geoPoint":{"lat":2.8033,"lon":101.7972}},{"city":"Kelantan","zip":"16150","country":"Malaysia"},{"city":"Kuala Lumpur","zip":"50603","country":"Malaysia","geoPoint":{"lat":3.1412,"lon":101.68653}},{"city":"Kuala Lumpur","zip":"59100","country":"Malaysia","geoPoint":{"lat":3.1412,"lon":101.68653}},{"city":"Kuala Pahang","zip":"25100","country":"Malaysia","geoPoint":{"lat":3.5321,"lon":103.4619}},{"city":"Petaling Jaya","zip":"46150","country":"Malaysia","geoPoint":{"lat":3.10726,"lon":101.60671}},{"city":"Petaling Jaya, Selangor","zip":"46050","country":"Malaysia"},{"city":"Pulau Pinang","zip":"11600","country":"Malaysia","geoPoint":{"lat":3.55,"lon":102.56667}},{"city":"Davao City","zip":"8000","country":"Philippines","geoPoint":{"lat":7.07306,"lon":125.61278}},{"city":"Desmarinas City","zip":"4114","country":"Philippines"},{"city":"Manila","zip":"1000","country":"Philippines","geoPoint":{"lat":14.6042,"lon":120.9822}},{"city":"Quezon City","zip":"1104","country":"Philippines","geoPoint":{"lat":14.6488,"lon":121.0509}},{"city":"San Juan City","zip":"1500","country":"Philippines","geoPoint":{"lat":14.6,"lon":121.0333}}]},"referencesModule":{"references":[{"pmid":"29654023","type":"DERIVED","citation":"Wen F, Zheng H, Zhang P, Hutton D, Li Q. OPTIMAL and ENSURE trials-based combined cost-effectiveness analysis of erlotinib versus chemotherapy for the first-line treatment of Asian patients with non-squamous non-small-cell lung cancer. BMJ Open. 2018 Apr 13;8(4):e020128. doi: 10.1136/bmjopen-2017-020128."},{"pmid":"26105600","type":"DERIVED","citation":"Wu YL, Zhou C, Liam CK, Wu G, Liu X, Zhong Z, Lu S, Cheng Y, Han B, Chen L, Huang C, Qin S, Zhu Y, Pan H, Liang H, Li E, Jiang G, How SH, Fernando MCL, Zhang Y, Xia F, Zuo Y. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol. 2015 Sep;26(9):1883-1889. doi: 10.1093/annonc/mdv270. Epub 2015 Jun 23."}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Erlotinib","description":"Participants received erlotinib 150 mg orally once daily until progressive disease or unacceptable toxicity."},{"id":"FG001","title":"Chemotherapy","description":"Participants received gemcitabine 1250 mg/m\\^2 intravenously (IV) on Days 1 and 8 and cisplatin 75 mg/m\\^2 IV on Day 1 of every 3 week cycle until disease progression, unacceptable toxicity, or a total of 4 cycles, whichever came first."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"110"},{"groupId":"FG001","numSubjects":"107"}]},{"type":"Received Treatment","achievements":[{"groupId":"FG000","numSubjects":"110"},{"groupId":"FG001","numSubjects":"104"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"109"},{"groupId":"FG001","numSubjects":"107"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"58"},{"groupId":"FG001","numSubjects":"57"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Other Reasons- Unspecified","reasons":[{"groupId":"FG000","numSubjects":"44"},{"groupId":"FG001","numSubjects":"38"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"9"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Full analysis set: All randomized participants.","groups":[{"id":"BG000","title":"Erlotinib","description":"Participants received erlotinib 150 mg orally once daily until progressive disease or unacceptable toxicity."},{"id":"BG001","title":"Chemotherapy","description":"Participants received gemcitabine 1250 mg/m\\^2 intravenously (IV) on Days 1 and 8 and cisplatin 75 mg/m\\^2 IV on Day 1 of every 3 week cycle until disease progression, unacceptable toxicity, or a total of 4 cycles, whichever came first."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"110"},{"groupId":"BG001","value":"107"},{"groupId":"BG002","value":"217"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"56.7","spread":"10.37"},{"groupId":"BG001","value":"55.8","spread":"10.41"},{"groupId":"BG002","value":"56.3","spread":"10.37"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"68"},{"groupId":"BG001","value":"65"},{"groupId":"BG002","value":"133"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"42"},{"groupId":"BG001","value":"42"},{"groupId":"BG002","value":"84"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Investigator-assessed Duration of Progression-free Survival","description":"The duration of progression-free survival was defined as the time from randomization to disease progression (PD) or death from any cause, whichever occurs first. PD was defined as: (1) At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this may include the baseline sum). The sum must also demonstrate an absolute increase of at least 5 mm. (2) An unequivocal progression of existing non-target lesions. When the patient has measurable disease, the overall tumor burden must have increased sufficiently to merit discontinuation of therapy. When the patient has only non-measurable disease, the increase in overall disease burden should be comparable in magnitude to the increase that would be required to declare PD for measurable disease. (3) The appearance of new malignant lesions.","populationDescription":"Full analysis set: All randomized participants.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Baseline to the data cut-off date of 20 Jul 2012 (1 year, 4 months)","groups":[{"id":"OG000","title":"Erlotinib","description":"Participants received erlotinib 150 mg orally once daily until progressive disease or unacceptable toxicity."},{"id":"OG001","title":"Chemotherapy","description":"Participants received gemcitabine 1250 mg/m\\^2 intravenously (IV) on Days 1 and 8 and cisplatin 75 mg/m\\^2 IV on Day 1 of every 3 week cycle until disease progression, unacceptable toxicity, or a total of 4 cycles, whichever came first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"107"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.0","lowerLimit":"8.3","upperLimit":"NA","comment":"The upper limit of the confidence interval could not be estimated due to too few events."},{"groupId":"OG001","value":"5.5","lowerLimit":"4.2","upperLimit":"7.1"}]}]}]},{"type":"SECONDARY","title":"Percentage of Responders as Assessed by the Investigator","description":"A responder was defined as a participant with either a complete response (CR) or a partial response (PR), as determined using the Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. A CR was defined as: (1) The disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \\< 10 mm. (2) The disappearance of all non-target lesions and normalization of tumor marker levels. All lymph nodes must be non-pathological in size (\\< 10 mm in the short axis). A PR was defined as: (1) At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. (2) The persistence of 1 or more non-target lesion(s) and/or maintenance of tumor marker levels above normal limits.","populationDescription":"Full analysis set: All randomized participants.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of responders","timeFrame":"Baseline to the data cut-off date of 19 Nov 2012 (1 year, 8 months)","groups":[{"id":"OG000","title":"Erlotinib","description":"Participants received erlotinib 150 mg orally once daily until progressive disease or unacceptable toxicity."},{"id":"OG001","title":"Chemotherapy","description":"Participants received gemcitabine 1250 mg/m\\^2 intravenously (IV) on Days 1 and 8 and cisplatin 75 mg/m\\^2 IV on Day 1 of every 3 week cycle until disease progression, unacceptable toxicity, or a total of 4 cycles, whichever came first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"107"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.2"},{"groupId":"OG001","value":"39.3"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Disease Control","description":"A participant with disease control was defined as a participant with either a complete response (CR), a partial response (PR), or stable disease (SD), as determined using RECIST v1.1. A CR was defined as the disappearance of all target lesions (TL). A PR was defined as at least a 30% decrease in the sum of the longest diameter of TLs taking as reference the Baseline sum longest diameter (SLD). SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest SLD since treatment started. For non-TLs, SD was defined as the persistence of 1 or more lesions. PD was defined as at least a 20% increase in the SLD of TLs, taking as reference the smallest SLD recorded since treatment started or the unequivocal progression of existing non-TLs. A SLD for all TLs will be calculated and reported as the Baseline SLD.","populationDescription":"Full analysis set: All randomized participants.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Baseline to the data cut-off date of 19 Nov 2012 (1 year, 8 months)","groups":[{"id":"OG000","title":"Erlotinib","description":"Participants received erlotinib 150 mg orally once daily until progressive disease or unacceptable toxicity."},{"id":"OG001","title":"Chemotherapy","description":"Participants received gemcitabine 1250 mg/m\\^2 intravenously (IV) on Days 1 and 8 and cisplatin 75 mg/m\\^2 IV on Day 1 of every 3 week cycle until disease progression, unacceptable toxicity, or a total of 4 cycles, whichever came first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"107"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.8"},{"groupId":"OG001","value":"82.2"}]}]}]},{"type":"SECONDARY","title":"Duration of Response","description":"Duration of response was defined as the time from the first documented complete response (CR) or partial response (PR) to the first documented disease progression (PD) or death, whichever occurs first. A CR was defined as the disappearance of all target lesions (TL). A PR was defined as at least a 30% decrease in the sum of the longest diameter (SLD) of TLs taking as reference the Baseline SLD. PD was defined as at least a 20% increase in the SLD of TLs, taking as reference the smallest SLD recorded since treatment started or the unequivocal progression of existing non-TLs.","populationDescription":"Full analysis set: All randomized participants. Only participants who had a complete response or partial response were included in the analysis.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Baseline to the data cut-off date of 19 Nov 2012 (1 year, 8 months)","groups":[{"id":"OG000","title":"Erlotinib","description":"Participants received erlotinib 150 mg orally once daily until progressive disease or unacceptable toxicity."},{"id":"OG001","title":"Chemotherapy","description":"Participants received gemcitabine 1250 mg/m\\^2 intravenously (IV) on Days 1 and 8 and cisplatin 75 mg/m\\^2 IV on Day 1 of every 3 week cycle until disease progression, unacceptable toxicity, or a total of 4 cycles, whichever came first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"107"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.8","lowerLimit":"7.0","upperLimit":"12.6"},{"groupId":"OG001","value":"4.2","lowerLimit":"2.8","upperLimit":"5.4"}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Overall survival was defined as the time from the date of randomization to the date of death from any cause.","populationDescription":"Full analysis set: All randomized participants.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Baseline to the end of the study (3 years, 1 month)","groups":[{"id":"OG000","title":"Erlotinib","description":"Participants received erlotinib 150 mg orally once daily until progressive disease or unacceptable toxicity."},{"id":"OG001","title":"Chemotherapy","description":"Participants received gemcitabine 1250 mg/m\\^2 intravenously (IV) on Days 1 and 8 and cisplatin 75 mg/m\\^2 IV on Day 1 of every 3 week cycle until disease progression, unacceptable toxicity, or a total of 4 cycles, whichever came first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"107"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.9","lowerLimit":"25.8","upperLimit":"30.5"},{"groupId":"OG001","value":"27.1","lowerLimit":"25.4","upperLimit":"30.9"}]}]}]},{"type":"SECONDARY","title":"Safety: Incidence of Adverse Events","reportingStatus":"NOT_POSTED","timeFrame":"36 months"},{"type":"SECONDARY","title":"Quality of Life: Functional Assessment of Chronic Illness Therapy - Lung (FACIT-L) Questionnaire","reportingStatus":"NOT_POSTED","timeFrame":"approximately 21 months"}]},"adverseEventsModule":{"frequencyThreshold":"5","description":"Safety analysis set: All participants who had received at least 1 dose of study medication.","eventGroups":[{"id":"EG000","title":"Erlotinib","description":"Participants received erlotinib 150 mg orally once daily until progressive disease or unacceptable toxicity.","seriousNumAffected":22,"seriousNumAtRisk":110,"otherNumAffected":99,"otherNumAtRisk":110},{"id":"EG001","title":"Chemotherapy","description":"Participants received gemcitabine 1250 mg/m\\^2 intravenously (IV) on Days 1 and 8 and cisplatin 75 mg/m\\^2 IV on Day 1 of every 3 week cycle until disease progression, unacceptable toxicity, or a total of 4 cycles, whichever came first.","seriousNumAffected":16,"seriousNumAtRisk":104,"otherNumAffected":96,"otherNumAtRisk":104}],"seriousEvents":[{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":110},{"groupId":"EG001","numAffected":0,"numAtRisk":104}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":110},{"groupId":"EG001","numAffected":0,"numAtRisk":104}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":110},{"groupId":"EG001","numAffected":1,"numAtRisk":104}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":110},{"groupId":"EG001","numAffected":2,"numAtRisk":104}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":110},{"groupId":"EG001","numAffected":0,"numAtRisk":104}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":110},{"groupId":"EG001","numAffected":4,"numAtRisk":104}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":110},{"groupId":"EG001","numAffected":3,"numAtRisk":104}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":110},{"groupId":"EG001","numAffected":1,"numAtRisk":104}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":110},{"groupId":"EG001","numAffected":0,"numAtRisk":104}]},{"term":"Abscess limb","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":110},{"groupId":"EG001","numAffected":0,"numAtRisk":104}]},{"term":"Gastrointestinal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":110},{"groupId":"EG001","numAffected":0,"numAtRisk":104}]},{"term":"Haemorrhoid infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":110},{"groupId":"EG001","numAffected":0,"numAtRisk":104}]},{"term":"Localised infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":110},{"groupId":"EG001","numAffected":0,"numAtRisk":104}]},{"term":"Nail bed infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":110},{"groupId":"EG001","numAffected":0,"numAtRisk":104}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":110},{"groupId":"EG001","numAffected":0,"numAtRisk":104}]},{"term":"Upper gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":110},{"groupId":"EG001","numAffected":0,"numAtRisk":104}]},{"term":"Small intestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":110},{"groupId":"EG001","numAffected":0,"numAtRisk":104}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":110},{"groupId":"EG001","numAffected":1,"numAtRisk":104}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":110},{"groupId":"EG001","numAffected":2,"numAtRisk":104}]},{"term":"Thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":110},{"groupId":"EG001","numAffected":1,"numAtRisk":104}]},{"term":"Angina pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":110},{"groupId":"EG001","numAffected":0,"numAtRisk":104}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":110},{"groupId":"EG001","numAffected":0,"numAtRisk":104}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":110},{"groupId":"EG001","numAffected":0,"numAtRisk":104}]},{"term":"Soft tissue injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":110},{"groupId":"EG001","numAffected":0,"numAtRisk":104}]},{"term":"Blood glucose increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":110},{"groupId":"EG001","numAffected":0,"numAtRisk":104}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":110},{"groupId":"EG001","numAffected":1,"numAtRisk":104}]},{"term":"Diabetes mellitus inadequate control","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":110},{"groupId":"EG001","numAffected":0,"numAtRisk":104}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":110},{"groupId":"EG001","numAffected":1,"numAtRisk":104}]},{"term":"Bone erosion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":110},{"groupId":"EG001","numAffected":0,"numAtRisk":104}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":110},{"groupId":"EG001","numAffected":0,"numAtRisk":104}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":110},{"groupId":"EG001","numAffected":0,"numAtRisk":104}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":110},{"groupId":"EG001","numAffected":0,"numAtRisk":104}]},{"term":"Atrial septal defect","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":110},{"groupId":"EG001","numAffected":0,"numAtRisk":104}]},{"term":"Uterine leiomyoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":110},{"groupId":"EG001","numAffected":1,"numAtRisk":104}]},{"term":"Spinal cord compression","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":110},{"groupId":"EG001","numAffected":0,"numAtRisk":104}]},{"term":"Bipolar disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":110},{"groupId":"EG001","numAffected":0,"numAtRisk":104}]},{"term":"Haemorrhoid operation","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":110},{"groupId":"EG001","numAffected":0,"numAtRisk":104}]}],"otherEvents":[{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":110},{"groupId":"EG001","numAffected":60,"numAtRisk":104}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":110},{"groupId":"EG001","numAffected":56,"numAtRisk":104}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":49,"numAtRisk":110},{"groupId":"EG001","numAffected":9,"numAtRisk":104}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":110},{"groupId":"EG001","numAffected":19,"numAtRisk":104}]},{"term":"Mouth ulceration","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":110},{"groupId":"EG001","numAffected":3,"numAtRisk":104}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":110},{"groupId":"EG001","numAffected":0,"numAtRisk":104}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":110},{"groupId":"EG001","numAffected":51,"numAtRisk":104}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":110},{"groupId":"EG001","numAffected":53,"numAtRisk":104}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":110},{"groupId":"EG001","numAffected":44,"numAtRisk":104}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":110},{"groupId":"EG001","numAffected":18,"numAtRisk":104}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":78,"numAtRisk":110},{"groupId":"EG001","numAffected":11,"numAtRisk":104}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":110},{"groupId":"EG001","numAffected":7,"numAtRisk":104}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":110},{"groupId":"EG001","numAffected":10,"numAtRisk":104}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":110},{"groupId":"EG001","numAffected":2,"numAtRisk":104}]},{"term":"Dermatitis acneiform","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":110},{"groupId":"EG001","numAffected":0,"numAtRisk":104}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":110},{"groupId":"EG001","numAffected":16,"numAtRisk":104}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":110},{"groupId":"EG001","numAffected":2,"numAtRisk":104}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":110},{"groupId":"EG001","numAffected":14,"numAtRisk":104}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":110},{"groupId":"EG001","numAffected":3,"numAtRisk":104}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":110},{"groupId":"EG001","numAffected":10,"numAtRisk":104}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":110},{"groupId":"EG001","numAffected":0,"numAtRisk":104}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":110},{"groupId":"EG001","numAffected":6,"numAtRisk":104}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":110},{"groupId":"EG001","numAffected":30,"numAtRisk":104}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":110},{"groupId":"EG001","numAffected":7,"numAtRisk":104}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":110},{"groupId":"EG001","numAffected":20,"numAtRisk":104}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":110},{"groupId":"EG001","numAffected":13,"numAtRisk":104}]},{"term":"Chest discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":110},{"groupId":"EG001","numAffected":3,"numAtRisk":104}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":110},{"groupId":"EG001","numAffected":14,"numAtRisk":104}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":110},{"groupId":"EG001","numAffected":7,"numAtRisk":104}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":110},{"groupId":"EG001","numAffected":9,"numAtRisk":104}]},{"term":"Paronychia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":110},{"groupId":"EG001","numAffected":0,"numAtRisk":104}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":110},{"groupId":"EG001","numAffected":6,"numAtRisk":104}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (14.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":110},{"groupId":"EG001","numAffected":8,"numAtRisk":104}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights."},"pointOfContact":{"title":"Medical Communications","organization":"Hoffmann-La Roche","email":"genentech@druginfo.com","phone":"800 821-8590"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069347","term":"Erlotinib Hydrochloride"},{"id":"D004358","term":"Drug Therapy"}],"ancestors":[{"id":"D011799","term":"Quinazolines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D013812","term":"Therapeutics"}]}},"hasResults":true}